Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 3Thoracic 2Gynecologic 2Genitourinary 2

Conditions

Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1

Interventions

pembrolizumab 50Nivolumab 21Docetaxel 11atezolizumab 7Ipilimumab 7avelumab 6Cyclophosphamide 6Paclitaxel 5Cetuximab 5Carboplatin 5fludarabine 4Radiotherapy 4Gemcitabine 4utomilumab 3spartalizumab 3lenvatinib 3durvalumab 3Trastuzumab 3Specimen Handling 3Interleukin-2 3Cisplatin 3Bevacizumab 3Albumin-Bound Paclitaxel 3zimberelimab 2tremelimumab 2tisotumab vedotin 2tislelizumab 2sargramostim 2obinutuzumab 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × tisotumab vedotin × Genitourinary × Clear all
NCT02001623 2021-12-29

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

Phase 1/2 Completed
195 enrolled 51 charts
GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03245736 2021-11-04

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Seagen Inc.

Phase 2 Completed
5 enrolled 8 charts
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡